Rate My Professor Su Yan

Su Yan serves as Assistant Research Professor of Biomedical Engineering at Pennsylvania State University - Erie. She earned a Bachelor of Medicine from Peking University in 2001. Su Yan's research interests include stem cell differentiation, bone and nerve tissue engineering, and biomaterials. Her work emphasizes developing advanced scaffolds and materials to facilitate tissue regeneration and repair.

Su Yan is the Principal Investigator on the National Institute of Neurological Disorders and Stroke-funded project 'Photoacoustic and epigenetic nerve scaffold for nerve regeneration,' running from 2022 to 2026. Her recent publications highlight innovations in regenerative medicine. In Science Advances (2026), she co-authored 'The genesis of citrated ultrathin hydroxyapatite nanorods,' exploring novel synthesis methods for nanomaterials. Another Science Advances paper (2025), 'Metabotissugenic citrate biomaterials orchestrate bone regeneration via citrate-mediated signaling pathways,' details citrate's role in bone repair pathways. In 2024, contributions include 'Citric Acid: A Nexus Between Cellular Mechanisms and Biomaterial Innovations' (Advanced Materials), reviewing citric acid applications; 'Scaffold design considerations for peripheral nerve regeneration' (Journal of Neural Engineering); and 'The use of hydrogel microspheres as cell and drug delivery carriers for bone, cartilage, and soft tissue regeneration' (Biomaterials Translational). Additional 2024-2023 works cover novel metal nanomaterials for angiogenesis and biodegradable osteopromotive bone putty.

Earlier research focused on cancer immunotherapy, with publications such as 'Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo' (Nature Biotechnology, 2018), 'TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies' (JCI Insight, 2018), 'Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer' (Clinical Cancer Research, 2017), 'Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1' (Nature Biotechnology, 2015), and others on TCR-mimic antibodies and WT1 targeting from 2013-2014. These efforts underscore her expertise in transitioning from oncology therapeutics to biomaterial-driven regeneration.